{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"92.9","upperLimit":"99.0","value":"97.3"},{"groupId":"OG001","lowerLimit":"90.2","upperLimit":"99.8","value":"98.6"}]}],"title":"1 year"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"86.7","upperLimit":"95.7","value":"92.4"},{"groupId":"OG001","lowerLimit":"88.0","upperLimit":"99.2","value":"96.9"}]}],"title":"3 years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"83.1","upperLimit":"93.5","value":"89.4"},{"groupId":"OG001","lowerLimit":"78.9","upperLimit":"95.4","value":"90.0"}]}],"title":"5 years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"description":"Overall survival is defined as the time from the date of randomization to the date of death (including the survival follow-up period) per Kaplan-Meier (KM).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants randomized to asciminib 40mg BID","id":"OG000","title":"Asciminib"},{"description":"Participants randomized to bosutinib 500mg QD","id":"OG001","title":"Bosutinib"}],"paramType":"NUMBER","populationDescription":"The FAS comprised of all randomized participants. According to the intent to treat principle, participants were analyzed according to the treatment and stratum were assigned at randomization.","reportingStatus":"POSTED","timeFrame":"From the first dose of treatment to study completion, up to 5 years","title":"Overall Survival (OS) Per Event Free Percentage Per Kaplan-Meier Estimates","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}